Correction to: Oncogene
This article was originally published under standard licence, but has now been made available under a CC BY 4.0 license. The PDF and HTML versions of the paper have been modified accordingly.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Johnson, C.E., Dunlop, E.A., Seifan, S. et al. Correction: Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir–bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death. Oncogene 38, 3102 (2019). https://doi.org/10.1038/s41388-018-0598-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-018-0598-0
